PATENT BOOST FOR MEDIGARD

Written on the 13 October 2010 by Tom Reid

PATENT BOOST FOR MEDIGARD

MEDIGARD Limited (MGZ) has received a huge boost in its prospects for distributing a second product into the United States following a patent approval in South Africa.

The publically-listed medical tech company’s 3ml retractable syringe has today been granted exclusive patent protection in the African republic until 2027.

CEO Peter Emery says South Africa is not a priority market and the approval ‘came out of the blue’, but the development bodes well for a successful application in the United States.

Medigard recently cracked the US market after signing a manufacturing and distribution deal for its innovative blood collection device (BCD).

Following a successful US Food and Drug Administration (FDA) application, the BCD distributor Outcome Solutions would have first rights to the retractable syringe.

“The BCD is the first Medigard product and is absolutely ready to go, whereas the 3ml retractable syringe is a little behind in development,” says Emery.

“But it is a key product and patent approval in South Africa is a positive indicator that the application will also be successful in other markets. We apply for patents on our products in multi-jurisdictions; it just so happens that South Africa was the first to approve it.”

While the priority won’t shift away from the United States, Emery says the approval furthers Medigard’s long-term prospects.

“It is a global plan and South Africa being a developed nation is a viable market for us,” he says.

“The rest of Africa is a more interesting market in that it’s less developed, but in great need of our retractable syringe product that stops the spread of Aids caused by reusing syringes.

“The big challenge however is that there is no money in these regions for manufacturing and distribution. For this type of product to work in all the African markets it would take the United Nations or a similar humanitarian group to provide the funding to get them to all the districts and villages.”

After launching a capital raising venture in the form of a shareholder rights issue, Medigard is still around $600,000 short of the $1.57 million required to get the first run of US manufacturing underway.

Emery says the company is exploring all avenues available to it in order to raise the additional funding.


Author: Tom Reid

Latest News

NEW CLASS OF EDUCATION NURTURES ENTREPRENEURS OF TOMORROW

THE rise in youth unemployment has affirmed the importance of entrepreneurship education, and south-east Queenslan...

DUET GROUP SUBJECT OF $7.3 BILLION TAKEOVER OFFER

HONG Kong's Cheung Kong Infrastructure has launched a $7.3 billion cash bid for one of Australia's largest en...

G8 SHARES BUOYED BY FORECAST PROFIT RECOVERY

CHILDCARE centre operator G8 Education (ASX:GEM) has revealed it is on track to post a pre-tax profit of up to $16...

BELLAMY'S FINDS EXPORTING BABY FORMULA INTO CHINA IS NO CHILD'S PLAY

BELLAMY'S (ASX: BAL) shares have suffered a 40 per cent drop in value today after the company hit a regulatory...

Related News

JB HI-FI IS THE GOOD GUY IN $870 MILLION ACQUISITION

ELECTRONICS giant JB Hi-Fi has formally completed its $870 million acquisition of home appliance chain The Good Gu...

ACCC ACTS AGAINST MERITON'S RIGGED REVIEWS

MERITON Property Services is under fire from Australia's main consumer watchdog, after it allegedly engaged in mi...

ACCC FIRES WARNING SHOT TO IVF PROVIDERS

IVF clinics have been put on notice by consumer watchdog, the Australian Competition and Consumer Commission (ACCC...

BIG W CEO QUITS AFTER 11 MONTHS

SALLY MacDonald has resigned as chief executive of BIG W ending her tenure at the helm of the struggling discount ...

Contact us

Email News Update Sign Up Contact Details

Subscribe to our mailing list

* indicates required
Email Format

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter